Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
28.19
-0.75 (-2.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arrowhead Pharma
< Previous
1
2
3
4
5
Next >
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023
April 12, 2023
Via
Benzinga
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
April 04, 2023
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts.
Via
The Motley Fool
Analyst Ratings for Arrowhead Pharma
March 21, 2023
Via
Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
February 07, 2023
Via
Benzinga
Earnings Outlook For Arrowhead Pharmaceuticals
February 03, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
December 06, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
March 21, 2023
Via
Benzinga
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
February 15, 2023
Via
Benzinga
Why Omeros Are Trading Higher By 32%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 06, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) jumped 156% to $4.3600. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 41.5% to $3.54.
Via
Benzinga
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
November 29, 2022
Via
Benzinga
Analyst Ratings for Arrowhead Pharmaceuticals
November 29, 2022
Via
Benzinga
Energizer, Children's Place And Other Big Stocks Moving Lower On Monday
February 06, 2023
U.S. stocks traded lower, with the Dow Jones dropping over 150 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Earnings Scheduled For February 6, 2023
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
Earnings Preview For Arrowhead Pharmaceuticals
November 25, 2022
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 09, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
January 09, 2023
Via
Benzinga
Why Arrowhead Pharmaceuticals Stock Is Diving Today
January 09, 2023
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) shares are down 20% Monday after the company announced topline results from the SEQUOIA Phase 2 study of fazirsiran in patients with
Via
Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
Earnings Scheduled For November 28, 2022
November 28, 2022
Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals
August 08, 2022
Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter:
Via
Benzinga
Arrowhead Pharmaceuticals: Q3 Earnings Insights
August 04, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Where Arrowhead Pharmaceuticals Stands With Analysts
May 24, 2022
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
Arrowhead Pharmaceuticals: Q2 Earnings Insights
May 10, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
April 30, 2022
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings...
Via
Talk Markets
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.